These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19266174)

  • 1. [The authorization of clinical trials by the federal authorities].
    Schriever J; Schwarz G; Steffen C; Krafft H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):377-86. PubMed ID: 19266174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical research. Effects of European legislation and current developments].
    Sudhop T; Enzmann H; Klar R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):375-6. PubMed ID: 19343281
    [No Abstract]   [Full Text] [Related]  

  • 3. [Decree on the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use].
    Schwerdtfeger WK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):147-54. PubMed ID: 15726455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Quality requirements for investigational medicinal products. The state authorities' point of view].
    Neuhaus J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):189-95. PubMed ID: 15726460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GCP inspections of clinical trials].
    Schwarz G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):181-8. PubMed ID: 15726459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germany opposes EU plans for regulating clinical trials owing to lack of ethical standards.
    Tuffs A
    BMJ; 2012 Oct; 345():e6640. PubMed ID: 23033377
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view].
    Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th Law Amending the German Drug Law].
    Geisler I; Hofmann HP; Nickel L
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):141-6. PubMed ID: 15726454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reorganization of the procedures and the tasks of the responsible ethics committees after the 12th AMG amendment. Concepts of the permanent working group of the medical ethics committees in Germany].
    Wessler I; Burger R; Doppelfeld E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):155-67. PubMed ID: 15726456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Responsibilities of coordination centers for clinical studies and their status in general practice].
    Ohmann C
    Internist (Berl); 2002 Apr; 43(4):498-505. PubMed ID: 12053406
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quality requirements governing non-commercial clinical trials within the framework of clinical drug development in humans in the EU. Challenges, opportunities, and questions experienced by treatment centres].
    Boos J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):196-203. PubMed ID: 15726461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-marketing authorisation submission assessments in Europe.
    Morgan L
    Therapie; 2005; 60(3):205-8. PubMed ID: 16128260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Implementation status of Regulation EU 536/2014 in the member states].
    Stahl E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):836-840. PubMed ID: 28638933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conducting clinical trials in Singapore.
    Woo KT
    Singapore Med J; 1999 Apr; 40(4):310-3. PubMed ID: 10487091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Trials Legislation - preparing for the revision of the European Directive Scheduled for 2011.
    Bilbault P; Belorgey C; Zannad F; Golinelli D; Pletan Y;
    Therapie; 2010; 65(4):301-8, 291-9. PubMed ID: 20854751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Principles of the EU Clinical Trials Regulation No 536/2014 : What will change?].
    Mende A; Frech M; Riedel C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):795-803. PubMed ID: 28685215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint.
    Legler UF
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical trials for medicinal products. New European and national legal rules].
    Kreutz G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):524-9. PubMed ID: 15887061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in the German Medicinal Product Act imposed by the EU regulation on clinical trials].
    Nickel L; Seibel Y; Frech M; Sudhop T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):804-811. PubMed ID: 28664271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.